

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/578,105
				Filing Date	January 10, 2007
				First Named Inventor	Sharma et al.
				Art Unit	1654
				Examiner Name	Andrew D. Kosar
				Attorney Docket Number	1674/2
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/578,105	
			Filing Date	January 10, 2007	
			First Named Inventor	Sharma et al.	
			Art Unit	1654	
			Examiner Name	Andrew D. Kosar	
Sheet	2	of	3	Attorney Docket Number	1674/2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Atkinson et al., <i>Peptide Inhibitors of CDK2-cyclin A that Target the Cyclin Recruitment-Site: Structural Variants of the C-Terminal Phe.</i> <u>Bioorganic & Medicinal Chemistry Letters</u> . Vol. 12 pgs.:2501-2505 (2002).	
	4	Boffa et al., <i>Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer.</i> <u>Clinical Cancer Research</u> . Vol. 10 pgs.:293-300 (2004).	
	5	Brown et al., <i>Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.</i> <u>PNAS</u> . Vol. 100, No. 25 pgs.:15113-15118 (2003).	
	6	Chen et al., <i>Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.</i> <u>PNAS</u> . Vol. 96 pgs.:4325-4329 (1999).	
	7	Dudkin et al., <i>Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition.</i> <u>Clinical Cancer Research</u> . Vol. 7 pgs.:1758-1764 (2001).	
	8	Elit, <i>CCI-779 Wyeth.</i> <u>Current Opinion in Investigational Drugs</u> . Vol. 3, No. 8 pgs.:1249-1253 (2002).	
	9	Gali-Muhtasib, H., and Bakkar, Nadine, <i>Modulating Cell Cycle: Current Applications and Prospects for Future Drug Development.</i> <u>Current Cancer Drug Targets</u> . Vol. 2 pgs.:309-336 (2002).	
	10	Huang, S., and Houghton, P.J., <i>Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic.</i> <u>Current Opinion in Investigational Drugs</u> . Vol. 3, No. 2 pgs.:295-304 (2002).	
	11	McInnes et al., <i>Peptidomimetic Design of CDK Inhibitors Targeting the Recruitment Site of the Cyclin Subunit.</i> <u>Current Medicinal Chemistry – Anti-Cancer Agents</u> . Vol. 3 pgs.:57-69 (2003).	
	12	Punt et al., <i>Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.</i> <u>Annals of Oncology</u> . Vol. 14 pgs.:931-937 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,105
				Filing Date	January 10, 2007
				First Named Inventor	Sharma et al.
				Art Unit	1654
				Examiner Name	Andrew D. Kosar
Sheet	3	of	3	Attorney Docket Number	1674/2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13	Sehgal et al., <i>Rapamycin (AY-22,989), A New Antifungal Antibiotic. II. Fermentation, Isolation and Characterization. The Journal of Antibiotics</i> . Vol. 28, No. 10 pgs.:727-732 (1975).	
	14	Sielecki et al., <i>Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. Journal of Medicinal Chemistry</i> . Vol. 43, No. 1 pgs.:1-18 (2000).	
	15	Vézina et al., <i>Rapamycin (AY-22,989), A New Antifungal Antibiotic. I. Taxonomy of the Producing Streptomyces and Isolation of the Active Principle. The Journal of Antibiotics</i> . Vol. 28, No. 10 pgs.:721-726 (1975).	
	16	Wiederrecht et al., <i>Mechanism of action of rapamycin: New insights into the regulation of G₁-phase progression in eukaryotic cells. Progress in Cell Cycle Research</i> . Vol. 1 pgs.:53-71 (1995).	
	17	Zheleva et al., <i>Highly potent p21^{WAF1}-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A. Journal of Peptide Research</i> . Vol. 60 pgs.:257-270 (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.